Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052666/SGN-MesoC2 in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052666/SGN-MesoC2 in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HBM-9033 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Harbour BioMed; Seagen

Most Recent Events

  • 23 May 2025 According to a Nona Biosciences media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 21 Feb 2025 Planned End Date changed from 1 Nov 2028 to 16 Feb 2029.
  • 21 Feb 2025 Planned primary completion date changed from 1 Nov 2028 to 17 Feb 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top